- Home
- CANF vs FAMI Comparison
CANF vs FAMI Comparison
Compare CANF & FAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- FAMI
- Stock Information
- Founded
- CANF 1994
- FAMI 2015
- Country
- CANF Israel
- FAMI China
- Employees
- CANF N/A
- FAMI N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- FAMI Packaged Foods
- Sector
- CANF Health Care
- FAMI Consumer Staples
- Exchange
- CANF Nasdaq
- FAMI Nasdaq
- Market Cap
- CANF 7.9M
- FAMI 2.1M
- IPO Year
- CANF N/A
- FAMI 2018
- Fundamental
- Price
- CANF $1.09
- FAMI $1.70
- Analyst Decision
- CANF Strong Buy
- FAMI
- Analyst Count
- CANF 2
- FAMI 0
- Target Price
- CANF $14.00
- FAMI N/A
- AVG Volume (30 Days)
- CANF 422.0K
- FAMI 94.0K
- Earning Date
- CANF 05-13-2025
- FAMI 05-13-2025
- Dividend Yield
- CANF N/A
- FAMI N/A
- EPS Growth
- CANF N/A
- FAMI N/A
- EPS
- CANF N/A
- FAMI N/A
- Revenue
- CANF $674,000.00
- FAMI $64,131,332.00
- Revenue This Year
- CANF $461.72
- FAMI N/A
- Revenue Next Year
- CANF N/A
- FAMI N/A
- P/E Ratio
- CANF N/A
- FAMI N/A
- Revenue Growth
- CANF N/A
- FAMI N/A
- 52 Week Low
- CANF $1.22
- FAMI $1.43
- 52 Week High
- CANF $4.69
- FAMI $11.28
- Technical
- Relative Strength Index (RSI)
- CANF 34.28
- FAMI 44.42
- Support Level
- CANF $1.13
- FAMI $1.55
- Resistance Level
- CANF $1.19
- FAMI $1.80
- Average True Range (ATR)
- CANF 0.11
- FAMI 0.14
- MACD
- CANF -0.02
- FAMI 0.05
- Stochastic Oscillator
- CANF 1.35
- FAMI 41.67
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About FAMI Farmmi Inc.
Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe, and the Middle East under the Forasen and Farmmi brands.